Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Lymphoma
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- Cervical Carcinoma
- Colon Carcinoma
- Colorectal Carcinoma
- Endometrial Carcinoma
- Esophageal Carcinoma
- Exocrine Pancreas Carcinoma
- Gastric Carcinoma
- Glioma
- Head and Neck Carcinoma
- Hematopoietic and Lymphoid Cell Neoplasm
- Kidney Carcinoma
- Liver Carcinoma
- Lung Carcinoma
- Lymphoma
- Malignant Uterine Corpus Neoplasm
- Malignant Uterine Neoplasm
- Melanoma
- Multiple Myeloma
- Ovarian Carcinoma
- Prostate Carcinoma
- Rectal Carcinoma
- Recurrent Bladder Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Cervical Carcinoma
- Recurrent Colon Carcinoma
- Recurrent Colorectal Carcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Gastric Carcinoma
- Recurrent Glioma
- Recurrent Head and Neck Carcinoma
- Recurrent Liver Carcinoma
- Recurrent Lung Carcinoma
- Recurrent Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Malignant Uterine Corpus Neoplasm
- Recurrent Melanoma
- Recurrent Multiple Myeloma
- Recurrent Ovarian Carcinoma
- Recurrent Pancreatic Carcinoma
- Recurrent Prostate Carcinoma
- Recurrent Rectal Carcinoma
- Recurrent Skin Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Multiple Myeloma
- Skin Carcinoma
- Thyroid Gland Carcinoma
Interventions
- DRUG: Adavosertib
- DRUG: Afatinib
- DRUG: Afatinib Dimaleate
- DRUG: Binimetinib
- PROCEDURE: Biopsy Procedure
- PROCEDURE: Biospecimen Collection
- DRUG: Capivasertib
- PROCEDURE: Computed Tomography
- DRUG: Copanlisib
- DRUG: Copanlisib Hydrochloride
- DRUG: Crizotinib
- OTHER: Cytology Specimen Collection Procedure
- DRUG: Dabrafenib
- DRUG: Dabrafenib Mesylate
- DRUG: Dasatinib
- DRUG: Defactinib
- DRUG: Defactinib Hydrochloride
- PROCEDURE: Echocardiography Test
- DRUG: Erdafitinib
- DRUG: Fexagratinib
Sponsor
National Cancer Institute (NCI)